In his new role, Gregory will drive partnerships for the company’s large-scale molecule biologics business across Europe
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
The new site will increase Syngene's total single-use bioreactor capacity to 50,000L
Overall investment in the US facility is estimated around US$50 million
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
The companies will combine Nanoform’s Biologics platform with the Celanese VitalDose Drug Delivery platform to further optimize controlled release of biologics
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
The acquisition is a crucial step in LTS' strategy to broaden its portfolio of drug delivery platforms.
The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
Innovative Capsugel Enprotect capsule can simplify the manufacturing process to accelerate drug development and expedite first-in-human timelines
Subscribe To Our Newsletter & Stay Updated
